-
Aadi Bioscience Announces Closing of Merger with Aerpio Pharmaceuticals and $155M Private Placement
Market news
firstwordpharmaAugust 27, 2021
Aadi Bioscience, Inc. ("Aadi") (Nasdaq: AADI) today announced the closing of its previously announced merger with Aerpio Pharmaceuticals, Inc. (previously traded on the Nasdaq Capital Market under "ARPO").
-
Bolt Biotherapeutics and Innovent Biologics Announce Collaboration to Develop Three New Oncology Boltbody ISAC Programs
Market news
firstwordpharmaAugust 27, 2021
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, and Innovent Biologics.
-
Humacyte Announces Successful Closing of Business Combination with Alpha Healthcare Acquisition Corp.
Market news
firstwordpharmaAugust 27, 2021
Humacyte, Inc. today announced the successful completion of its business combination (the "Business Combination") with Alpha Healthcare Acquisition Corp.
-
Airway Therapeutics Announces First Patient Dosed in Phase 1b Trial of AT-100 in Severe COVID-19 Patients
Market news
firstwordpharmaAugust 27, 2021
Airway Therapeutics, Inc. (Airway) announced dosing of the first patient on August 17, 2021 in the AT-100 (rhSP-D) Phase 1b trial in mechanically-ventilated COVID-19 patients.
-
Ontada Signs Strategic Agreement with Merck to Facilitate the Development of Data-Driven Insights to Impact Quality of Cancer Care
Market news
firstwordpharmaAugust 27, 2021
OntadaTM, McKesson's oncology and insights business, today announced a strategic agreement with Merck, known as MSD outside the United States and Canada, that will facilitate the development of real-world research excellence and innovation.
-
Incyte and MorphoSys Announce the European Commission Approval of Minjuvi (tafasitamab) in Combination With Lenalidomide for the Treatment of Adults With Relapsed or Refractory Diffuse Large B-Cell Ly
Market news
firstwordpharmaAugust 27, 2021
Incyte (Nasdaq:INCY) and MorphoSys AG (FSE:MOR; NASDAQ:MOR) today announced that the European Commission (EC) has granted conditional marketing authorization for Minjuvi® (tafasitamab) in combination with lenalidomide, followed by Minjuvi monotherapy.
-
US ships more than 2 mln more Covid vaccines to Africa
Market news
firstwordpharmaAugust 27, 2021
The White House said Thursday that the US is shipping more than 2 million doses of COVID-19 vaccines to Algeria, Ghana and Yemen, as reported This is Money.
-
Sorrento Exercises Exclusive Option Agreement With Texas A&M University for MPRO Inhibitors Against Sars-Cov-2 and all Variants of Concern
Market news
firstwordpharmaAugust 27, 2021
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that it has notified The Texas A&M University System ("TAMUS") of its exercise of the option to an exclusive license for the global development and commercialization of highly potent
-
First Danish doses delivered through COVAX arrive in Algeria
Market news
firstwordpharmaAugust 27, 2021
The first deliveries from a pledge of 1 million doses to be donated to COVAX by Denmark have arrived, with 57,600 doses of the AstraZeneca (AZ) vaccine to Algeria on 26 August. These will be closely followed by a delivery of 115,200 doses to Morocco.
-
Wockhardt and Jemincare partner for novel respiratory antibiotic Nafithromycin
Market news
firstwordpharmaAugust 27, 2021
Wockhardt Bio AG – a subsidiary of Wockhardt Limited, (“Wockhardt”), a worldwide leader in discovery of novel antibiotics and Jiangxi Jemincare Group Company Limited, China (“Jemincare”), have partnered for Wockhardt’s novel patented antibiotic WCK 4873.
Aadi Bioscience, Inc. ("Aadi") (Nasdaq: AADI) today announced the closing of its previously announced merger with Aerpio Pharmaceuticals, Inc. (previously traded on the Nasdaq Capital Market under "ARPO").
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, and Innovent Biologics.
Humacyte, Inc. today announced the successful completion of its business combination (the "Business Combination") with Alpha Healthcare Acquisition Corp.
Airway Therapeutics, Inc. (Airway) announced dosing of the first patient on August 17, 2021 in the AT-100 (rhSP-D) Phase 1b trial in mechanically-ventilated COVID-19 patients.
OntadaTM, McKesson's oncology and insights business, today announced a strategic agreement with Merck, known as MSD outside the United States and Canada, that will facilitate the development of real-world research excellence and innovation.
Incyte (Nasdaq:INCY) and MorphoSys AG (FSE:MOR; NASDAQ:MOR) today announced that the European Commission (EC) has granted conditional marketing authorization for Minjuvi® (tafasitamab) in combination with lenalidomide, followed by Minjuvi monotherapy.
The White House said Thursday that the US is shipping more than 2 million doses of COVID-19 vaccines to Algeria, Ghana and Yemen, as reported This is Money.
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that it has notified The Texas A&M University System ("TAMUS") of its exercise of the option to an exclusive license for the global development and commercialization of highly potent
The first deliveries from a pledge of 1 million doses to be donated to COVAX by Denmark have arrived, with 57,600 doses of the AstraZeneca (AZ) vaccine to Algeria on 26 August. These will be closely followed by a delivery of 115,200 doses to Morocco.
Wockhardt Bio AG – a subsidiary of Wockhardt Limited, (“Wockhardt”), a worldwide leader in discovery of novel antibiotics and Jiangxi Jemincare Group Company Limited, China (“Jemincare”), have partnered for Wockhardt’s novel patented antibiotic WCK 4873.
Pharma Sources Insight 08/2021
